Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Chi-Med Enrolls 527 Lung Cancer Patients for China Trial of Fruquintinib

publication date: Feb 13, 2018

Hutchison China MediTech (Chi-Med) completed patient enrollment in a China Phase III trial of fruquintinib as a treatment for patients with non-small cell lung cancer. The trial, which enrolled 527 NSCLC patients who have failed two earlier treatments, will administer fruquintinib as a single agent. Chi-Med has started a Phase II trial in NSCLC as an adjunct to Iressa® (gefitinib) as a first-line treatment for lung cancer. The CFDA has already accepted an NDA for fruquintinib in colorectal cancer. More details....

Stock Symbol: (AIM/NSDQ: HCM)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital